CD34: Difference between revisions
From haematologyetc.co.uk
(Created page with " <div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;"> :<span style="color:navy">'''Summary'''</span> :Often regarded as a marker of primitive phenotype, CD34 is expressed by many cases of ALL (around 50%) and slightly fewer cases of AML around (40%). CD34 is also expressed by regenerating cells in marrow, and particularly by regenerating B lymphocytes (haematogones), but is generally absent from mature haematopoietic cells....") |
No edit summary |
||
| Line 5: | Line 5: | ||
:<span style="color:navy">'''Summary'''</span> | :<span style="color:navy">'''Summary'''</span> | ||
:Often regarded as a marker of primitive phenotype, CD34 is expressed by many cases of ALL (around 50%) and slightly fewer cases of AML around (40%). CD34 is also expressed by regenerating cells in marrow | :Often regarded as a marker of primitive phenotype, CD34 is expressed by many cases of ALL (around 50%) and slightly fewer cases of AML around (40%). CD34 is also expressed by regenerating cells in marrow. It is particularly expressed by regenerating B lymphocytes (haematogones), but is generally absent from mature haematopoietic cells. | ||
Revision as of 12:43, 17 May 2023
- Summary
- Often regarded as a marker of primitive phenotype, CD34 is expressed by many cases of ALL (around 50%) and slightly fewer cases of AML around (40%). CD34 is also expressed by regenerating cells in marrow. It is particularly expressed by regenerating B lymphocytes (haematogones), but is generally absent from mature haematopoietic cells.
Normal expression and function
CD34 is a membrane protein that is likely to play a role in the retention of cells within the stem cell niche where it may also contribute to their subsequent maturation. CD34 is acquired at the stage of pluripotent stem cells and is retained by committed stem cells before being lost as the cells mature. CD34 is also expressed by mast cells and by some non-haematopoietic cells particularly endothelial cells.
Diagnostic role
- xxxxx
Other relevant information:
xxxxx
SUMMARY TABLES
Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name
| Expression in primitive cell types | |||||||
|---|---|---|---|---|---|---|---|
| AML | CMML | B ALL | Burkitt | T ALL | ETP ALL <I> | MPAL <I> | Hgns <I> |
| ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
| Expression in mature B cell neoplasms | |||||||
|---|---|---|---|---|---|---|---|
| CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
| ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
| Expression in mature T cell neoplasms* | ||||||
|---|---|---|---|---|---|---|
| ATLL | CTCL/Sezary | T-PLL | T-LGL | NK-LGL | ||
| ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ||
Notes: xxxxx